RxDoctor Payments Data

Jamee Martin, PA

Physician Assistant · Germantown, TNNPI 1346659505

Payments from drug & device makers

$7,751in general payments, 2019–2025

Across 218 payments — averaging $35.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • Medtronic$1K
  • Johnson & Johnson$813
  • Myriad Genetic Laboratories, Inc.$737
  • Dendreon Pharmaceuticals LLC$652
  • Teleflex LLC$571
  • plus $3K from 26 others

What the payments were for

  • Travel & lodging$1,30317%
  • Food & beverage$6,34982%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,751 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$565,533
Medicare patients
394
Services billed
22,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron39$30,323
OrgovyxRelugolix11$27,344
MyrbetriqMirabegron32$14,510
Methylphenidate Hcl59$1,318
Tamsulosin Hcl67$1,123
NitrofurantoinNitrofurantoin Macrocrystal16$662
Dutasteride14$572
Finasteride49$563
Alfuzosin Hcl ErAlfuzosin Hcl16$477
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav41$381
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$343
Ciprofloxacin Hcl43$274
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$225
Hydroxyzine Pamoate13$166
Fluconazole22$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$1,218$57,66750 claims
Astellas Pharma US IncMyrbetriq$50$14,51032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →